Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The Snowbirds Donate $47,500 at Their Fifth Annual Golf Tournament Weekend to Empower Underprivileged Youth Golfers

February 3, 2026

Toys ‘R’ Us Canada seeks creditor protection, owns vendors at least $120M

February 3, 2026

MP Nate Erskine-Smith ‘exploring’ Ontario Liberal leadership, seeks seat

February 3, 2026

Combined Arms Supports and Applauds Bipartisan Legislation to Create a National Veterans Strategy

February 3, 2026

Jeff Muth Elected Managing Member of Miller Johnson

February 3, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
Press Release

Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion

By News RoomFebruary 3, 20264 Mins Read
Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
Share
Facebook Twitter LinkedIn Pinterest Email
Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion

ST VINCENT AND THE GRENADINES, Caribbean, Feb. 03, 2026 (GLOBE NEWSWIRE) — Eleusis, the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026 on the island of Bequia in Saint Vincent and the Grenadines. Built on a single foundational principle — safety first — Eleusis offers a licensed, research immersion in a physician-supervised environment, set within a private tropical wellness sanctuary. Eleusis is accepting applications for the March 2026 cohort, with private inquiries welcomed.

Founded by Christina Thomas, chief experience officer; Angus Taylor, CEO; Charles Patti, chief of growth; and Craig Stenhouse, chief operating officer, Eleusis is a curated experiential sanctuary designed for rigorous, responsible consciousness exploration, featuring DMTx protocols. Eleusis is a medically-supervised research immersion created for experienced participants seeking a discreet, high-touch environment and a deeply structured program.

Developed by Dr. Andrew Gallimore in conjunction with Dr. Rick Strassman, DMTx technology has been explored in institutional research settings, including work associated with Imperial College London and Yale University, and has been described in published research as safe and tolerable under controlled conditions.

DMTx is an extended-state DMT experience enabled through controlled administration. DMT is a short-acting psychedelic compound that has been studied for its relationship to perception and consciousness. Using a target-controlled IV infusion to maintain a stable and regulated level over time, DMTx is designed to support a sustained, structured experience for observation, exploration, and integration — within defined medical and operational protocols.

At Eleusis, DMTx protocols are physician-supervised and supported by a trained care team, with monitoring and participant support designed around best practices in screening, preparation, and integration. Eleusis follows a precision-minded approach, including customized dosing parameters and structured pre/post experience support.

The six-day Eleusis experience is fully all-inclusive, so guests can focus fully on their journey of transformation and healing. The immersion covers a comprehensive medical and psychiatric screening; HUME band and biometric tracking; personalized integration guide and pre-retreat materials; three DMTx experiences; daily group integration, yoga, and meditation; luxury accommodations in private villas or suites; gourmet, organic meals and beverages; four weeks of post-retreat integration calls; and expert assistance booking private charters.

A condensed, fully all-inclusive four-day essential experience is also available with two DMTx experiences. This is for seekers who have limited availability and still want to have a transformational experience with DMTx.

“We exist to empower pioneers, visionaries, and seekers to heal, create, expand, and lead from an awakened state,” said Taylor. “By integrating insights from inner experience with purposeful action in the world, we aim to help normalize responsible consciousness exploration — with safety and integrity at the center.”

“Eleusis represents a new chapter in self-discovery and consciousness exploration,” said Patti. “My own experiences changed the trajectory of my life. Eleusis is my way of creating a safe, structured space where others can explore intentionally, with the right medical oversight and integration support.”

“DMT is one of the most powerful tools for exploring the furthest reaches of consciousness, and DMTx transforms what was once a transient encounter into a platform for structured exploration,” said Gallimore. “From the beginning, my vision was that DMTx could move beyond research institutions and become accessible to those who wish to explore responsibly and intentionally. With Eleusis, that vision is now taking form.”

Eleusis brings together a globally respected interdisciplinary team, including Dr. Andrew Gallimore, PhD—inventor of DMTx and computational neurobiologist; Dr. Chris Timmermann, PhD—director of research, neuroscientist, and DMT phenomenology researcher (University College London); Alex Tomic—technology entrepreneur and research funder; Dr. Andrew Ferber, MD—psychiatry and integrative mental health; Bianca Abbott, NP—advanced practice nursing, with a focus on detox and fasting; Dr. Murray Heber, DC—director of flow and performance, neuroscience of performance and flow-state training; and Christina Thomas—co-founder and chief experience officer, overseeing participant experience and integration and COO and co-founder of MY Self Wellness.

For more information, visit www.eleusismind.com.

Media Contact:
Durée & Company, PR Consultant
954-723-9350 / [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16d5dd73-6f52-4ab6-95d5-96454887e745

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

The Snowbirds Donate $47,500 at Their Fifth Annual Golf Tournament Weekend to Empower Underprivileged Youth Golfers

Combined Arms Supports and Applauds Bipartisan Legislation to Create a National Veterans Strategy

Jeff Muth Elected Managing Member of Miller Johnson

Constellation Data Labs Announces Agreement to Provide National Data Services to REMAX, Acquires Seventy3 and Gadberry Group

Concurrent Technologies Corporation Transitions Metal Injection Molded Ammunition Technology to Ultra Defense Corp

Fraser Valley home prices back to pandemic-era levels under weight of economic headwinds and sustained inventory

DTN Weather Hub Strengthens Utility Outage Response and Grid Reliability

Banner Health taps finance leader for strategy and growth role

Atomos 19” Shogun AV-19 Rackmount Monitor-Recorder-Switcher Just Announced, More Info at B&H Photo

Editors Picks

Toys ‘R’ Us Canada seeks creditor protection, owns vendors at least $120M

February 3, 2026

MP Nate Erskine-Smith ‘exploring’ Ontario Liberal leadership, seeks seat

February 3, 2026

Combined Arms Supports and Applauds Bipartisan Legislation to Create a National Veterans Strategy

February 3, 2026

Jeff Muth Elected Managing Member of Miller Johnson

February 3, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

The four best Super Bowl TV deals we found

February 3, 2026

Constellation Data Labs Announces Agreement to Provide National Data Services to REMAX, Acquires Seventy3 and Gadberry Group

February 3, 2026

Concurrent Technologies Corporation Transitions Metal Injection Molded Ammunition Technology to Ultra Defense Corp

February 3, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version